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There is increasing evidence that human tumors possess tumor-associated neo-antigens. The host mounts
an immunological response to these antigens, as evidenced by the detection ofcirculating humoral antibodies
in a variety of human neoplasia.
An indirect immunofluorescent antibody technique was employed to detect antibodies to tumor-associated
antigens in the sera of patients with malignant gliomas. Viable single cell suspensions were used to demon-
strate antibodies to surface contents of tumor cells and cell preparations were snap-frozen at - 1600 C to
demonstrate antibodies to cytoplasmic components oftumor cells. After incubation with serum, the prepara-
tions were treated with polyvalent sheep antihuman globulin conjugated to isomer-l-fluorescein isothiocya-
nate, washed, and examined with a Leitz incident fluorescent microscope.
Of the 17 sera from histologically proven malignant glial neoplasm patients, 2 (11%) were positive for an
autologous surface antibody reaction. Five (23%) of 21 were positive for an autologus cytoplasmic antibody,
however, 10 (47%) of 21 of the sera gave a positive reaction for cross-reacting cytoplasmic antibodies when
tested with a battery of tumor cells obtained from different patients with malignant glial tumors.
No reaction was observed with normal brain tissue. Absorption studies indicated the presence of a tumor-
associated antigen.
This study demonstrated that certain patients with malignant gliomas possess circulating antibodies to
cytoplasmic components of their own tumor cells. The fact that a number of sera cross-reacted with tumor
cells obtained from different patients suggests that antigenic cross-reactivity exists between malignant glioma
cells from different patients. It is suggested that with further refinement, immunofluorescent detection of
antibodies could evolve as a useful diagnostic adjunct in malignant glioma.
INTRODUCTION
A wide variety of human neoplasms have been shown to carry tumor-associated
antigens and to elicit, in the host, cell-mediated [1] and humoral [2] immunity as well
as serum factors [3] that are capable of abrogating in vitro manifestations of cell-
mediated immunity.
Humoral antibodies directed against human tumor cells or constituents have been
extensively sought and have been demonstrated in sera of patients with a variety of
neoplasms [4-7]. Though the possible in vivo role ofsuch antibodies is unclear, there
is suggestive evidence that humoral antibodies play a role in the control of disease
and prognosis of human tumors [8,9].
We are reporting our preliminary study which indicates that sera of patients with
malignant glial neoplasms have antibodies demonstrable by indirect immunofluores-
cence. These antibodies are directed against intracytoplasmic antigens ofautologous
and allogeneic tumor cells.
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MATERIALS AND METHODS
Tissue specimens were obtained from a consecutive series of 21 patients with
malignant glial tumors. The mean age of the population was 50 years with a range of
33-71 years. All patients had relatively brief clinical histories (less than 6 months)
and had been on dexamethasone therapy for a period of 2-5 days with a mean of 3
days. Tissue specimens were obtained at the time ofsurgery when subtotal excision of
the tumors was accomplished. Serum specimens were obtained in a simultaneous
fashion. To insure uniformity of opinion regarding the pathological material, all
specimens were reviewed by the director ofthe Cajal Neuropathological Laboratories
at the Los Angeles County-University of Southern California Medical Center. The
degree of malignancy observed was considered to be at the level ofeither a malignant
astrocytoma or glioblastoma multiforme in all cases.
In addition to the serum samples from 21 patients with malignant glial tumors,
serum specimens were available from 6 patients with meningioma, 10 patients with
breast carcinoma, and 14 patients with melanoma. A group of 15 individuals with
non-malignant disease was included as controls.
After dissection and removal of tissue for routine pathological evaluation, the
specimen was transferred in Hank's balanced salt solution: The tissue was mechani-
cally minced to form a single cell suspension. The final concentration of cells was
adjusted to 1 x 106 cells per ml.
A portion of the cell suspension was used to prepare cell smears for cytoplasmic
immunofluorescence studies. A drop of cell suspension was placed on a microscopic
glass slide, air dried, and snap frozen in a mixture of iso-pentane and liquid nitrogen
at - 1600 C [2]. The slides were stored at -70° C. Prior to use, the slides were
removed from cold storage, air dried, and washed in Phosphate buffered saline (PBS)
for 10 minutes with constant agitation.
INDIRECT IMMUNOFLUORESCENCE
An indirect immunofluorescence method was used on snap frozen tumor cells or
single cell suspensions to demonstrate antibodies to cytoplasmic or surface constitu-
ents, respectively. The reactions between patients' serum and autologous, as well as
allogeneic tumor cells, were examined. In the immunofluorescent test, tumor cell
suspensions or smears were incubated with serum diluted 1:8 in PBS for 20 minutes,
rinsed, and incubated with sheep anti-human Ig conjugated to isomer-l-fluorescein
isothiocyanate (obtained from Burroughs Wellcome Laboratories). For control
purposes, tumor cells were also incubated each time with known positive and
negative sera and with fluorescein labeled anti-human globulin alone without prior
incubation with human serum.
Sheep anti-human globulin Ig conjugated to isomer-l-fluorescein isothiocyanate
was obtained from Burroughs Wellcome Laboratories. These conjugates were further
purified by chromatography as previously described [10].
Microscopic examination was done with a Leitz incident microscope with a high
intensity UV lamp using an HBO mercury lamp with a K490 primary exciting filter
and K515 suppression filter. The positive reaction gave brilliant apple-green fluores-
cence.
Cell counts were performed to determine the percentage ofcells which fluoresced
after the application ofthe test serum. A preparation was considered positive if 30%
or more cells showed positive fluorescence.
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SERUM ABSORPTION
Routinely, a small portion of glial tumor from each case was removed and stored
at-70° C for absorption studies. Small pieces oftissue obtained from temporal and
frontal lobectomies performed for lesions oftraumatic etiology were pooled and used
as a source of normal brain tissue. Pooled tumor tissue or normal brain tissue were
suspended in PBS to remove blood and minced with a pair ofscissors in a petri dish.
The coarse homogenate was centrifuged at 5,000 x G for 30 minutes at 40 C, the pellet
was resuspended in PBS, and homogenized in a Waring blender. The emulsion was
frozen and thawed several times and centrifuged at 7,000 x G for 30 minutes at 40 C.
The pellet was lypholized and stored at 40 C.
For use, the required quantity of lypholized material was resuspended in 10
volumes of PBS for 30 minutes, centrifuged at 7,000 x G for 30 minutes, and the
supernatant discarded. It may be pointed out here that during this procedure, we may
have lost the soluble component of cellular material.
In absorption tests, 0.5 ml of serum diluted to 2 mlwith PBS was mixed with 1 gm
of reconstituted homogenate. The mixture was stirred gently for 3 hours at room
temperature, overnight at 40 C, and centrifuged at 7,000 x G for 30 minutes to
recover the maximum amount of serum [7].
RESULTS
Results, summarized in Table 1, indicate that 2 (11%) of 17 glioma sera gave a
positive immunofluorescence reaction to surface components, and 5 (23%) out of 21
sera reacted with intracytoplasmic components of autologous tumor cells.
When large pieces of tumor were available, serum antibody reactions to allogeneic
tumor cells were studied.
Sera from 11 glioma patients were tested with tumor cells from 4 patients. No
reaction for serum antibodies to surface antigen of allogeneic tumor-cells were
noticed. Similarly, for studies of serum antibodies to cytoplasmic antigens of tumor
cells, sera from 6 patients were reacted with their tumor cells. The results are shown
in Table 2.
Sera from patients M.D., C.L., T.M., and J.B. did not show autologous reaction
(reaction with the patient's own cells). However, sera from two patients, T.M., and
V.B., showed allogeneic reaction (reaction with cells obtained from other patients)
for antibodies to intracytoplasmic antigens (Table 2).
Antigen preparations from patients A.C., E.G., and V.B. showed higher frequency
of cross-reaction for antibodies to cytoplasmic antigens (i.e., cells from patient A.C.
reacted with all 6 sera, whereas cells from E.G. and V.B. reacted with at least 4 out of
6 sera tested) than those obtained from patients M.D., C.L., and T.M. (Table 2). In
this study, antigen preparations from former groups of patients (i.e., A.C., E.G., and
V.B.) were used routinely to study serum antibodies to cytoplasmic antigens of
malignant glioma. Frequency ofthe reactive sera was comparable in all 3 substrates.
Ten (47%) of 21 sera from glioma patients showed positive fluorescent reaction,
however, 1 (7%) of 15 sera from a normal population, 1 (10%) out of 10 sera from
patients with carcinoma of the breast, 2 (14%) of 14 sera from patients with mela-
noma, and 1 out of 6 sera from meningioma patients were reactive with cytoplasmic
components of tumor cells (Table 3).
Titer of serum antibodies to intracytoplasmic antigens among glioma patients
varied between 1:8 to 1:32. Immunofluorescence was principally limited to the
cytoplasm of the cells (Fig. 1).
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TABLE I
Indirect Immunofluorescent Reaction of Sera Obtained
from Malignant Glioma Patients with Patient's Own Tissue
Nature of Reaction # of Sera Tested Sera Reacted % Positive
Membrane Reaction 17 2 11
Cytoplasmic Reaction 21 5 23
TABLE 2
Indirect Immunofluorescent Reactions of Sera Obtained from Glioma Patients with
Cytoplasmic Components of Autologous and Allogeneic Tumor Cells
Sera Cells
A.C. E.G. M.lD. C.L. T.)M. V.B.
A.C. --+ +
E.G. + ++ +
M.D. + T_--+
C.L. + _
T.M. + + + +
V.B. + + + +
NOTE: (The results within the central diagonal lines are reactions with autologous cells.)
TABLE 3
Indirect Immunofluorescence Reaction of Sera Obtained from Malignant Glioma
Patients and Various Control Groups Reacting with Malignant Glioma Cells
Fluorescence Localization
Cell Surface Cytoplasm
Diagnosis Sera Reacted! % Positive Sera Reacted! % Positive
Total Total
Malignant Glioma 0/11 0 10/21 47
Meningioma - - 1/6 16
Normal - - 1/15 6
Ca. Breast - - 1/10 10
Melanoma - - 2/14 14
In order to establish the specificity of the reaction, glioma sera were reacted with
normal brain tissue. In none of the sera was a reaction realized.
In another experiment, strongly positive sera (titer 1/32) from 3 glioma patients
were absorbed separately with normal human muscle, brain, and pooled glioma
tissue and reacted again with tumor cells (Table 4). While absorption with normal
tissues had little or no effect, the absorption of sera with tumor cells significantly
removed the reactivity.
It is impossible to say that the number of glial cells used in the absorption
experiment was equal between the glioma tissue and normal brain. However, no
immunofluorescence was appreciated when positive sera were reacted against normal
brain tissue. Additionally, the amounts ofantibody which we are attempting to study
are of such a small order of magnitude that absorption with normal brain, which is
composed predominantly of glial cells, would presumably be equivalent to absorp-
tion with equal amounts of glioma tissue.
Evidence for specificity of the reactions for glioma antigen was further sought by
reacting sera ofglioma patients with cell preparations obtained from various types ofMALIGNANT GLIAL NEOPLASMS
I
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FIG. 1. Intracytoplasmic immunofluorescent reaction demonstrated in snap frozen glioma cell preparation.
TABLE 4
Indirect Immunofluorescence: The Effect of Serum Absorption with Various Tissue
Preparations on the Titer of the Cytoplasmic Antibodies to Malignant Glioma Cells
Tissue Used for
Absorption Sera from Patient
A B C
Original Titer 1/32 1/32 1/32
Muscle 1/32 1/32 1/16
Normal Brain 1/16 1/32 1/16
Pool Malignant
Glioma Tissue 1/4 1/4 1/2
human tumor tissue, i.e., melanoma, carcinoma of the breast, and lung and ocular
melanoma. The frequency of reactions of glioma patients' sera in tests with other
types of tumor cells was low (Table 5) as compared to that of glioma tumor cells.
DISCUSSION
In our study, the majority of sera from glioma patients (15 sera of 17 patients)
lacked circulating antibodies to surface antigens of glioma cells (Table 1). Similar
findings have been reported by Delpech et al. [11], and Eggers [12] in 1972 who, using
indirect immunofluorescent antibody technique, reported that only I of 17 sera of
glioma patients gave evidence of antibodies to membrane antigens.
In these studies, the lack ofdetection ofcirculating antibodies to surface antigens
of tumor cells could be due to the already in vivo binding of globulin to surface
antigens of tumor cells as demonstrated by Tabuchi and Kirsch [13]. Utilizing a
rabbit anti-human IgG source for FAB fragments, Tabuchi and Kirsch conjugated
antibody with horseradish peroxidase and demonstrated the presence of the peroxi-
dase reaction product predominately on the membranes of 4 of 9 glioblastoma
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TABLE 5
Indirect Immunofluorescence: Reaction of Sera Obtained from Glioma Patients with
Cytoplasmic Components of Tumor Cells Obtained from Patients with
Melanoma, Ocular Melanoma, Carcinoma of Breast, or Carcinoma of Lung
Sera Tested # Positive % Positive
Melanoma 10 0 0
Ocular Melanoma 10 1 10
Ca. Breast 12 0 0
Ca. Lung 15 2 13
preparations. This observation suggested the presumptive antigen-antibody complex
on the surface ofglioblastoma cells in vivo and implied that IgG can cross a vascular
capillary barrier in certain human glioblastomas.
We routinely reacted the tumor cells with fluorescein isothiocyanate (FITC)
conjugated to antihuman globulin. These tests failed to demonstrate antigen-
antibody binding to membranes of tumor cells.
Our results demonstrated that a large number of sera (10 of21) from patients with
malignant gliomas reacted with cytoplasmic antigens of allogeneic tumors, whereas
reactivity among sera from various control groups was significantly reduced, ranging
from 6% in a normal population to 16% in meningioma patients (Table 3). This
difference in the fluorescence reaction among patients with gliomas and control
donors strongly suggests the presence ofcirculating antibodies to antigens associated
with the cytoplasmic components of the tumor cells in these patients.
Prior to use, the substrate (i.e., cell smear preparations) as well as tissue homogen-
ate for absorption studies was washed in PBS. This process may eliminate a part or
all of the soluble fraction of the antigenic component. Therefore, it is possible that
this test may be detecting antibodies to a part ofthe antigenic component ofglioma
cells, i.e., possibly an insoluble fraction.
The observations that in our studies positive sera did not react with the normal
brain tissue and that the absorption of these sera with normal brain tissue did not
abolish the activity while absorption with tumor tissue removed the activity (Table 4),
suggest that the serum antibodies reported here are tumor associated. Allogeneic
cross-reactivity of antibodies to cytoplasmic antigens in various glioma patients
suggests the presence of common, tumor-associated antigens in these patients.
Reactivity of some of the sera with intracytoplasmic antigens ofallogeneic tumor
cells and not with autologous tumor cells is difficult to explain. It is conceivable that
glioma cells may have more than one antigenic component (i.e., individual, specific,
or common) among all gliomas, and that the prevalence of antibodies to various
components may vary in relation with the various stages of the disease.
Tissue typing, which was not performed on the patients, might have been useful in
assessing the presence or absence of antibodies in these sera.
A number of studies have been directed toward the detection and definition of a
humoral response to glial tumors. In 1965, Mitts and Walker [14] undertook investi-
gations which demonstrated that culture growth of malignant glial neoplasms was
inhibited by the addition ofautologous sera. Kornblith et al. [15] demonstrated that
postoperative sera caused hyperpolarization of the membranes of glial cells in
culture. In another publication, Kornblith et al. [16] applied an in vitro microcyto-
toxicity assay to the study ofthe immune response in human astrocytomas. The sera
of 17 of 26 patients harboringglial neoplasms produced significant cytotoxicity when
tested against allogeneic astrocytoma cells. These studies demonstrated no particular
relationship to the histological grade ofthe patient's tumor. Three ofthe 46 sera from
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normal controls, and 1 of 13 sera from patients with non-neoplastic central nervous
system disease were also cytotoxic in this series. None of 4 sera from meningioma
patients was positive.
The reactions of6% of sera in the normal control group (though in low titer) with
glioma cells requires an explanation. Similar findings have been previously reported
in other human neoplasms [2,6]. It is possible that these sera reacted nonspecifically
with tumor cells. It is also equally possible that the detection of antibodies to
cytoplasmic antigens in such cases may be related to future malignancy. In such
instances, therefore, followup of fluorescent antibody study, including absorption of
these sera with normal and tumor tissue and careful clinical examination, would be of
special interest.
Studies on a large population of patients with a number of central nervous system
neoplasms are in progress in our laboratory. If the present findings prove to be
consistent in a large group ofglioma patients, the implications of such studies could
be of immense importance in screening of patients and consequently for the early
detection and management of these neoplasms.
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